Collectively, the results presented in these prior studies (i.e., molecular mechanisms promoting AR activity in HER2-high tumor cells) reflect years of prolonged ADT for recurrent PCa, such that the therapeutic window for cotargeting HER2 and AR would have been lost. This evidence concerns the gene AR and neoplasm.